CalAsia Pharmaceuticals Inc
CalAsia Pharmaceuticals, Inc. is an employee owned early stage pharmaceutical company concentrates on the rapid discovery of drug-like small molecules by using its core technologies. This was founded in 2009 & located at San Diego. Allan E. Rubensteinis the present MD of CalAsia Pharmaceuticals,Inc.
Its core technology platform effectively combines functional fragment screening with X-ray crystallography co-crystallization guided by a streamlined structure-based design approach to rationally design and synthesize New Chemical Entities (NCEs) with drug-like properties.
CalAsia also employs an academically-advanced stem cell technology platform to evaluate lead drug candidates for proof of concept using patient-derived human induced pluripotent stem cells (iPSC).
CalAsia team has decades of drug discovery experience, including exceptional training and acquired skills in sophisticated structure-based drug design, as evidenced by a prominent history of involvement with numerous successful drug discovery programs, which have produced multiple clinical candidates, as well as one marketed drug.
CalAsia's Services: The CalAsia team provides its core expertise, which includes cloning, recombinant protein expression (E. coli, baculovirus & yeast), protein purification, biochemical assays, cellular assays, fragment screening, X-ray crystallography co-crystallization, and structure-based drug design methodology to the drug discovery community through contract research.